We like to think of consultants as neutral advisors, number crunchers in suits who stay above the fray. But McKinsey? They stepped into the fire, took payment, and handed out gasoline.
The Opioid Crisis and McKinsey: A Dangerous Partnership
Between 2004 and 2019, McKinsey advised Purdue Pharma on strategies to dramatically increase OxyContin sales. This wasn’t about operational efficiency or supply chain logistics. No, this was about moving pills — fast. The firm delivered detailed reports with titles like “Launch Strategy for MS Contin” and “Abuse-Deterrent Formulations,” documents that outlined how to counter declining prescriptions by pushing higher doses and targeting the highest-prescribing doctors. Yes, they knew.
McKinsey consultants reportedly used terms like “turbocharging” OxyContin sales, language so aggressive it sounds more like a startup pitch than medical ethics. One internal memo suggested using the term “whales” to describe top-prescribing physicians. We’re not talking about ocean mammals here. We’re talking about doctors writing thousands of opioid prescriptions a year, many in regions already drowning in addiction.
And that’s exactly where the moral rot sets in. McKinsey wasn’t just advising — they were optimizing a machine designed to profit from dependency. They weren’t bystanders. They were engineers.
You might say, “But they were just consultants. They didn’t manufacture the drug.” True. Yet their recommendations directly influenced how aggressively Purdue marketed OxyContin, especially during the peak of the overdose epidemic. Between 1999 and 2020, nearly 500,000 people in the U.S. died from opioid overdoses. In some counties, pill mills outnumbered pharmacies. McKinsey’s involvement didn’t start the crisis, but they helped scale it.
Internal Docs Reveal Aggressive Sales Tactics
Federal investigations and whistleblower lawsuits uncovered McKinsey’s internal presentations urging Purdue to “aggressively promote” higher-dose pills, which were more addictive and profitable. These weren’t passive suggestions. Consultants tracked prescription data in real time, creating dashboards to monitor which doctors were slowing down — and which needed “coaching.”
One 2013 strategy document recommended doubling sales of high-dose OxyContin by 2018. Another called for a “patient starter coupon program” — yes, coupons for addictive opioids, like a two-for-one deal at the pharmacy. The thing is, these weren’t theoretical exercises. Purdue implemented many of these ideas.
The 0 Million Settlement
In 2021, McKinsey agreed to pay $573 million — later adjusted to nearly $600 million — to settle federal and state investigations. That’s the largest penalty ever paid by a consulting firm in U.S. history. But here’s the kicker: no admission of wrongdoing. The firm paid to make the problem go away, not to admit they helped make it worse.
And let’s be clear about this — $600 million sounds like a lot. But for a firm that raked in $13.5 billion in revenue in 2022, it’s a rounding error. It’s less than 5% of a single year’s earnings. Punishment? Hardly. It’s a licensing fee for bad behavior.
Why McKinsey’s Role Was Different — And Worse
Consulting firms work with controversial clients all the time. Oil companies, defense contractors, tobacco firms — they’ve all had their moments. But McKinsey’s work with Purdue crossed a line because it wasn’t just about profitability. It was about human lives. Actual people. Families torn apart. Entire communities hollowed out by addiction.
What makes this scandal stick isn’t just the money or the settlements. It’s the culture it exposed. The reports showed McKinsey consultants treating the opioid crisis like a spreadsheet challenge — “How do we grow market share in a declining segment?” — without grappling with the real-world consequences.
Because we expect more from firms that claim to shape the future of business. McKinsey’s tagline is “We help create positive, enduring change in the world.” That changes everything when you realize they were helping create a different kind of change — one measured in body counts.
A Pattern of Ethical Drift
This wasn’t an isolated misstep. McKinsey has faced scrutiny for advising South African financial firms linked to state corruption, working with authoritarian regimes like Saudi Arabia and Rwanda, and helping private equity firms strip assets from hospitals while hiking prices. The opioid case is just the most visible symptom.
The problem is, the incentives are all wrong. McKinsey’s consultants are rewarded for closing deals and hitting revenue targets. Not for asking “Should we be doing this?” That’s left to someone else — usually too late.
The “See No Evil” Defense
The firm’s leadership has repeatedly claimed they were unaware of how their advice was being used. But internal emails tell a different story. In 2017, one consultant wrote, “We know our work contributed to the opioid crisis.” Another admitted, “Our recommendations led to increased sales of high-dose OxyContin.” These weren’t rogue employees. These were partners, operating within the system.
So when McKinsey says “we didn’t know,” you have to wonder — how hard were they looking?
McKinsey vs. Other Consulting Firms: A Question of Scale
Let’s compare. Bain and BCG have also faced criticism. Bain had ties to Purdue too, though they ended their relationship earlier and cooperated with investigators. BCG has worked with fossil fuel companies and weapons manufacturers. But neither has paid a settlement remotely close to McKinsey’s $600 million.
And that’s not just about money. It’s about duration, depth, and denial. McKinsey advised Purdue longer, more intensively, and with less transparency. They didn’t just offer strategy — they embedded teams inside the company, attending executive meetings and drafting sales scripts.
It’s a bit like comparing a mechanic who changes your brakes to one who modifies your car to run on fumes and then sells you a map to the nearest cliff.
Revenue Ties That Bind
McKinsey earned an estimated $1 billion from Purdue over 15 years. That kind of money creates loyalty — not to ethics, but to the bottom line. When a client represents millions in annual fees, saying “no” becomes career suicide.
BCG and Bain don’t have the same scale of exposure. Their opioid-related work was shorter, less central, and less lucrative. That doesn’t make them saints. But it does make McKinsey the outlier — the one that went all in.
Frequently Asked Questions
Did McKinsey employees face criminal charges?
No McKinsey employees have faced criminal charges related to the opioid scandal. The Department of Justice pursued civil penalties, not prosecutions. Some former Purdue executives have been charged, even convicted. But McKinsey walked away with a fine and a tarnished name. Data is still lacking on whether internal disciplinary actions occurred — the firm hasn’t said.
Is McKinsey still working in healthcare?
Yes. Despite the fallout, McKinsey maintains a major healthcare practice. They advise hospitals, insurers, and pharma companies. In 2023, they opened a new health analytics division. That said, some clients have quietly distanced themselves. A few nonprofits dropped McKinsey after media exposés. But the firm’s core business remains intact. Reputation damage? Real. But not fatal.
What reforms has McKinsey implemented?
The firm says it now has stricter ethical review boards and client intake procedures. They claim to reject 20% of potential engagements on ethical grounds. Experts disagree on whether that’s meaningful. Some call it window dressing. Others see it as a start. Honestly, it is unclear how much has actually changed inside the firm’s decision-making culture.
The Bottom Line
I find this overrated — the idea that McKinsey has been “held accountable.” A fine is not justice. Not when people are still dying from opioid use. Not when over 10 million Americans misused prescription opioids in 2022 alone. McKinsey helped design the engine of that crisis. They got paid. They stayed silent. And then they paid a fraction of their profits to move on.
The scandal isn’t just about one client or one report. It’s about what happens when elite firms confuse influence with immunity. McKinsey still advises governments, still shapes policy, still recruits top talent from Ivy League schools. And we let them. Why?
Because we want to believe smart people make good choices. But sometimes, they just make smart spreadsheets. And that’s the real scandal. Not the corruption. The complacency. The quiet acceptance that this is just how the game is played.
I am convinced that the biggest scandal isn’t behind us — it’s the fact that we’re already forgetting.